- Home
- QRVO vs ABVX Comparison
QRVO vs ABVX Comparison
Compare QRVO & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | QRVO | ABVX |
|---|---|---|
| Founded | 1957 | 2013 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Semiconductors | |
| Sector | Technology | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3B | 9.6B |
| IPO Year | 1997 | N/A |
Fundamental Metrics
Financial Performance| Metric | QRVO | ABVX |
|---|---|---|
| Price | $88.10 | $123.43 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 14 | 12 |
| Target Price | $98.23 | ★ $112.83 |
| AVG Volume (30 Days) | 1.2M | ★ 1.7M |
| Earning Date | 01-27-2026 | 08-11-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 2.30 | N/A |
| Revenue | ★ $3,663,072,000.00 | $7,073,400.00 |
| Revenue This Year | $3.31 | $6.80 |
| Revenue Next Year | $2.34 | N/A |
| P/E Ratio | $38.32 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $49.46 | $4.77 |
| 52 Week High | $106.30 | $138.49 |
Technical Indicators
Market Signals| Indicator | QRVO | ABVX |
|---|---|---|
| Relative Strength Index (RSI) | 50.24 | 59.90 |
| Support Level | $85.03 | $107.06 |
| Resistance Level | $90.30 | $138.49 |
| Average True Range (ATR) | 1.89 | 7.15 |
| MACD | 0.53 | 0.19 |
| Stochastic Oscillator | 66.56 | 58.28 |
Price Performance
Historical ComparisonAbout QRVO Qorvo Inc.
Qorvo represents the combined entity of RF Micro Devices and TriQuint Semiconductor, which merged in January 2015. The company specializes in radio frequency filters, power amplifiers, and front-end modules used in many of the world's most advanced smartphones. Qorvo also has a suite of products sold into a variety of nonsmartphone end markets, such as wireless base stations, cable TV and networking equipment, and infrastructure and military applications.
About ABVX Abivax SA American
Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.